Please login to the form below
cancer
This page shows the latest cancer news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer
as a treatment for kidney cancer for use within the Cancer Drugs Fund. ... number of cancer immunotherapies including Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).
Latest news
-
Roche’s Tecentriq combo scores FDA approval for melanoma
When receiving a cancer immunotherapy combined with targeted therapies, patients with BRAF V600 mutation-positive advanced melanoma were able to live for more than 15 months without their disease worsening," said ... 2015. Aside from melanoma, Roche has
-
AstraZeneca escapes pandemic impact as new drugs bolster revenues
Total revenue for the company’s oncology medicines climbed 28% for the half year to $5.32bn, with a majority of that increase fuelled by growth of its new cancer treatments
-
BMS/bluebird bio resubmit FDA application for myeloma CAR-T
In addition, 100% of evaluable patients achieved early minimal residual disease-negative status at day 28 post-infusions, which means that there was no detectable cancer cells in their bone marrow.
-
AZ strengthens Daiichi Sankyo partnership with new ADC deal
TROP2. According to AZ, TROP2 is over-expressed in the majority of non-small cell lung cancers (NSCLC) and breast cancers. ... We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly
-
GSK’s anti-BCMA drug leads crowded CHMP recommendations
into first-line extensive-stage small cell lung cancer (ES-SCLC), in combination with a choice of chemotherapies.
More from news
Approximately 686 fully matching, plus 3,071 partially matching documents found.
Latest Intelligence
-
Gut instincts lead Takeda to GI pipeline success
It is targeted for market approval in 2022. The promise continues with a phase 3 trial deploying Entyvio as a support for stem cell transplantation cancer treatments that are vulnerable to
-
Addressing the payer-regulator evidence gap in early-stage cancer
By Jason Ward. In 2018, more than four million people across Europe were diagnosed with some form of cancer. ... disease. Is there a way to accelerate patient access to medicines for earlystage cancers in the interim?
-
AI and genomics: a revolution in drug discovery and development
Pfizer, for example, has used a machine learning system called IBM Watson to search for cancer drug targets.
-
Working together against COVID-19
It can infer patients are at fault for not fighting hard enough if they lose their battle with cancer, for example.
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... targets of small cell lung
More from intelligence
Approximately 8 fully matching, plus 316 partially matching documents found.
Latest appointments
-
McCann Health France strengthens team with two new hires
Prior to McCann Health France, she served as scientific director at various international health organisations, including the ARC Foundation for Cancer Research and the French National Cancer Institute.
-
Genmab hires first chief operating officer
Anthony shares our determination to bring truly differentiated new cancer treatments to the market that will deliver on our commitment to improve patients’ lives while fostering a culture of excellence and
-
New hires at Crescendo, Healx and Galecto
Galecto. Galecto, a clinical stage company developing treatments for fibrosis and cancer, has appointed Bertil Lindmark as its new chief medical officer.
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
Horning received her MD from University of Iowa School of Medicine, and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University. ... In addition, she brings the perspective of a leading physician who has spent more
-
Lucid Group announces new hires at its creative and digital agency Bluedog
Finally, Victoria William joins Bluedog as a senior account executive. William has two years’ experience working at an independent creative healthcare agency, and also has a MSc in cancer cell biology.
More from appointments
Approximately 5 fully matching, plus 207 partially matching documents found.
Latest from PMHub
-
July 2020: diversity and inclusion in clinical trials round-up
Black people are among those who typically suffer poorer health outcomes from lung cancer. ... This will massively help improve trust while educating people on the importance of cancer clinical trials.
-
Mednet Group’s growth spurt
in cancer biology and she has experience working as a research technician in the field of malignant haematology. .
-
The importance of health literacy in patient recruitment materials
Figure 1. Type 2 Diabetes (top) and Cancer (bottom) posters that were presented.
-
Secondary effects of COVID-19 on the healthcare system and patients
We are getting to the point where we need to start considering the long-term effects on the healthcare system when making decisions. By now, your social media feeds are probably full of COVID-19-related news articles, opinion pieces, and memes (not
-
EU Pharmaceutical Strategy Roadmap
EU OMP Regulation Review. Whilst the EU Regulation on OMPs is specifically referenced in the Roadmap, the document looks more at cancer and the unmet need that is perceived due to
More from PMHub
Approximately 37 fully matching, plus 183 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- How will the events and exhibitions industry change post-Coronavirus?
- J&J’s COVID-19 vaccine generates positive pre-clinical results
- AstraZeneca escapes pandemic impact as new drugs bolster revenues
- Roche’s Actemra fails in late-stage severe COVID-19 study
- Novavax reports promising phase 1 results for coronavirus vaccine
- Merck enters agreement with Hanmi for investigational NASH drug
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Virtual Engagement At Porterhouse: Reflections on the past few months
- July 2020: diversity and inclusion in clinical trials round-up
- Eli Lilly begins COVID-19 prevention trial in nursing homes
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- ...
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
